ASO Author Reflections: Limited Survival Benefit from Neoadjuvant Chemotherapy in ER+/HER2- Breast Cancer. - Zou Y; Bian L; Zhang H; Tang H; Peng C; Wang J (Annals of surgical oncology, 2025)